Metabolic patterns on [ 18 F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.

Adrien HolzgreveJulian TaugnerLukas KäsmannPhilipp MüllerAmanda TufmanNiels ReinmuthMinglun LiMichael WinkelmannLena M UnterrainerAlexander E NietoPeter BartensteinWolfgang G KunzJens RickeClaus BelkaChukwuka EzeMarcus UnterrainerFarkhad Manapov

Published in: European journal of nuclear medicine and molecular imaging (2023)

Durvalumab maintenance treatment after CRT leads to diverging tumoral metabolic changes, but also increases splenic metabolism and leads to a higher proportion of findings suggestive of irAE compared to patients without durvalumab. Due to significantly prolonged survival with durvalumab, survival analysis will be substantiated in correlation to metabolic changes as soon as more clinical events are present.

Keyphrases

small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
rectal cancer
prognostic factors
combination therapy
radiation therapy
advanced non small cell lung cancer
atrial fibrillation